Clinical and immunological characteristics of children diagnosed with-Type 1 diabetes during the COVID-19 pandemic.
COVID-19
Sars-Cov-2
antibodies
autoimmunity
diabetes mellitus type 1
immunology
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
revised:
13
10
2023
received:
17
07
2023
accepted:
20
10
2023
pubmed:
29
10
2023
medline:
29
10
2023
entrez:
28
10
2023
Statut:
aheadofprint
Résumé
To find clinical and immunological signatures of the SARS-CoV-2 and the COVID-19 pandemic on children newly diagnosed with type 1 diabetes (T1D). A single-centre, retrospective, observational study comparing the clinical and immunological characteristics of children diagnosed with T1D the year before and during the first 2 years of the COVID-19 pandemic. Data extracted from the medical records included clinical and demographic parameters, COVID-19 PCR results and the presence of anti-islet, thyroid and celiac-related antibodies. Also obtained from the medical records was a family history of T1D, celiac disease and autoimmune thyroid disease in a first-degree family member. A total of 376 children were diagnosed with T1D during the study period. A total of 132 in the pre-COVID era and 246 in the first 2 years of the pandemic. At diagnosis, the pH in children with DKA was lower, and HbA1c tended to be higher in the COVID-19 group compared to the pre-COVID-19 group (7.30 [7.18, 7.35] vs 7.33 [7.19, 7.36], p = 0.046) and (110.9 [86.9, 129.5] vs 100 [80.3, 129.5], p = 0.067]) respectively. Multiple islet antibodies (IA) were significantly more common among patients in the pre-COVID-19 group compared to the COVID-19 group (72% vs 61%, p = 0.032). Tissue transglutaminase antibodies were more common among children diagnosed in the COVID-19 compared to the pre-COVID group (16.6% vs 7.9%, p = 0.022). Our findings suggest that SARS-CoV-2 and the environmental alterations caused by the pandemic affected the clinical characteristics and the immunological profile of children diagnosed with T1D. It is, therefore, plausible that the virus plays a role in the autoimmune process causing T1D.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15250Informations de copyright
© 2023 Diabetes UK.
Références
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):9-82.
Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32(4):457-467.
Kondrasho A, Hyöty H. Role of viruses and other microbes in the pathogenesis of type 1 diabetes. Int Rev Immunol. 2014;33(4):284-295.
Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus-why the β cells? Nat Rev Endocrinol. 2016;12(5):263-273.
Boddu SK, Aangabadkar G, Kuchay MS. New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab Syndr. 2020;14(6):2211-2217.
Lugar M, Eugster A, Achenbach P, et al. SARS-COV-2 infection and development of islet autoimmunity in early childhood. JAMA. 2023;330(12):1151-1160. doi:10.1001/jama.2023.16348
Krischer JP, Lernmark A, Hagopian WA, et al. Akolkar B for the teddy study group SARS-CoV-2-no increased islet autoimmunity or type 1 diabetes in teens. NEJM. 2023;389(5):474-476.
Weiss A, Donnachie E, Beyerlein A, Ziegler AG, Bonifacio E. Type 1 diabetes incidence and risk in children with a diagnosis of COVID-19. JAMA. 2023;329(23):2089-2091.
Dżygało K, Nowaczyk J, Szwilling A, Kowalska A. Increased frequency of severe diabetic ketoacidosis at type 1 diabetes onset among children during COVID-19 pandemic lockdown: an observational cohort study. Pediatr Endocrinol Diabetes Metab. 2020;26(4):167-175.
Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of COVID-19 and risk of diabetic ketoacidosis in new-onset type 1 diabetes. Pediatrics. 2021;148(3):208-217.
Steenblock C, Richter S, Berger I, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021;12(1):3534.
Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. Diabetes Care. 2022;45(8):1762-1771. doi:10.2337/dc21-0969
Boboc AA, Novac CN, Marin AG, et al. SARS-CoV-2 positive serology and islet autoantibodies in newly diagnosed pediatric cases of type 1 diabetes mellitus: a single-center cohort study. Int J Mol Sci. 2023;24(10):8885. doi:10.3390/ijms24108885
Hollstein T, Schulte DM, Schulz J, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab. 2020;2:1021-1024.
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17:11-30.
Muller JA, Groß R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3:149-165.
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193-199.
Kamrath C, Ros bauer J, Tittel SR, et al. Frequency of autoantibody-negative type 1 diabetes in children, adolescents, and young adults during the first wave of the COVID-19 pandemic in Germany. Diabetes Care. 2021;44:1-7.
Ye Q, Wang DJ. Epidemiological changes of common respiratory viruses in children during the COVID-19 pandemic. Med Virol. 2022;94(5):1990-1997.
Gavish Levinsky Y, Dizitzer Y, Dizitzer Y, et al. The COVID-19 pandemic dramatically reduced admissions of children with and without chronic conditions to general paediatric wards. Acta Paediatr. 2021;110:2212-2217.
Kuczmarski RJ, Ogden CL, Guo SS, et al. CDC growth charts for the United States: methods and development. Vital Health Stat. 2000;246(1):1-190.
Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479.
Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021;33(8):1565-1576.e5.
Tarique M, Suhail M, Naz H, et al. Where do T cell subsets stand in SARS-CoV-2 infection: an update. Front Cell Infect Microbiol. 2022;12:964265.
Minervina AA, Pogorely MV, Kirk AM, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat Immunol. 2022;23(5):781-790.
Shalitin S, Phillip M, Yackobovitch-Gavan M. Changes in body mass index in children and adolescents in Israel during the COVID-19 pandemic. Int J Obes (Lond). 2022;46:1160-1167.
Dilek SO, Gurbuz F, Turan I, Celiloglu C, Yuksel B. Changes in the presentation of newly diagnosed type 1 diabetes in children during the COVID-19 pandemic in a tertiary center in southern Turkey. JPEM. 2021;34(10):1303-1309. doi:10.1515/jpem-2021-0287
Saeedi N, Gohari NSF, Ghalibaf AAM, Dehghan A, Owlia MB. COVID-19 infection: a possible induction factor for development of autoimmune diseases? Immunol Res. 2023;71:547-553. doi:10.1007/s12026-023-09371-7
Rodríguez Y, Rojas M, Beltrán S, et al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun. 2022;132:102898.
Dobrowolska K, Zarębska-Michaluk D, Poniedziałek B, Jaroszewicz J, Flisiak R, Rzymski P. Overview of autoantibodies in COVID-19 convalescents. J Med Virol. 2023;95(6):e28864.
Goldman S, Pinhas-Hamiel O, Weinberg A, et al. Alarming increase in ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the first wave of the COVID-19 pandemic in Israel. Pediatr Diabetes. 2022;23(1):10-18. doi:10.1111/pedi.13296